Suppr超能文献

产前暴露于苯巴比妥的早产儿的神经发育结局

Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure.

作者信息

Shankaran Seetha, Papile Lu-Ann, Wright Linda L, Ehrenkranz Richard A, Mele Lisa, Lemons James A, Korones Sheldon B, Stevenson David K, Donovan Edward F, Stoll Barbara J, Fanaroff Avroy A, Oh William, Verter Joel

机构信息

Wayne State University, Detroit, MI, USA.

出版信息

Am J Obstet Gynecol. 2002 Jul;187(1):171-7. doi: 10.1067/mob.2002.122445.

Abstract

OBJECTIVE

We previously demonstrated that antenatal phenobarbital does not decrease the risk of intracranial hemorrhage or early death in premature infants. The objective of the present study was to evaluate the impact of antenatal phenobarbital exposure on the neurodevelopmental outcome of premature infants born to women who were participating in the randomized clinical trial of antenatal phenobarbital exposure.

STUDY DESIGN

Infants were evaluated at 18 to 22 months corrected age with a standard neurologic examination and the Bayley scales of infant development measuring the mental developmental index and the psychomotor developmental index.

RESULTS

Of the 578 infants <34 weeks of gestational age who were born to women who were enrolled in the primary study, 7 infants died after discharge from the neonatal intensive care unit, and 135 infants were lost to follow-up. Infants who were lost to follow-up had a higher mean birth weight and gestational age and a lower maternal education, but the rates of intracranial hemorrhage were comparable to those infants who were evaluated. Among the infants who were evaluated (n = 436; 76%), the mean birth weight and gestational age, maternal education, and frequency and distribution of intracranial hemorrhage were similar in the antenatal phenobarbital exposed and placebo groups. Eighteen infants (8%) in the antenatal phenobarbital exposed group and 21 infants (11%) in the placebo group had cerebral palsy (P = not significant). There was no difference between the 2 groups in either the median Bayley II mental developmental index (85 in the antenatal phenobarbital and 86 in the placebo group) or the Psychomotor Developmental Index (91 in the antenatal phenobarbital and 91 in the placebo group). Infants with intracranial hemorrhage (23%) had significantly lower mental developmental index and psychomotor developmental index scores than infants with no intracranial hemorrhage, independent of antenatal phenobarbital exposure. In the total cohort of 436 infants, the presence of intracranial hemorrhage or periventricular leukomalacia was associated with lower mental developmental index and psychomotor developmental index scores; the presence of increasing birth weight, maternal education, and a complete course of antenatal steroids was associated with a higher mental developmental index score.

CONCLUSION

Antenatal phenobarbital exposure did not favorably or adversely affect the neurodevelopmental outcome of premature infants at 18 to 22 months of age.

摘要

目的

我们之前已证明产前使用苯巴比妥不会降低早产儿颅内出血或早期死亡的风险。本研究的目的是评估产前接触苯巴比妥对参与产前苯巴比妥接触随机临床试验的女性所生早产儿神经发育结局的影响。

研究设计

在矫正年龄18至22个月时,对婴儿进行标准神经学检查以及使用贝利婴儿发育量表测量智力发育指数和心理运动发育指数。

结果

在主要研究中登记入组的女性所生的578例孕周小于34周的婴儿中,7例婴儿在从新生儿重症监护病房出院后死亡,135例婴儿失访。失访婴儿的平均出生体重和孕周较高,母亲受教育程度较低,但颅内出血发生率与接受评估的婴儿相当。在接受评估的婴儿中(n = 436;76%),产前接触苯巴比妥组和安慰剂组的平均出生体重、孕周、母亲受教育程度以及颅内出血的频率和分布相似。产前接触苯巴比妥组有18例婴儿(8%)患有脑瘫,安慰剂组有21例婴儿(11%)患有脑瘫(P值无统计学意义)。两组在贝利II智力发育指数中位数(产前接触苯巴比妥组为85,安慰剂组为86)或心理运动发育指数(产前接触苯巴比妥组为91,安慰剂组为91)方面均无差异。有颅内出血的婴儿(23%)的智力发育指数和心理运动发育指数得分显著低于无颅内出血的婴儿,与产前是否接触苯巴比妥无关。在436例婴儿的整个队列中,颅内出血或脑室周围白质软化的存在与较低的智力发育指数和心理运动发育指数得分相关;出生体重增加、母亲受教育程度提高以及产前类固醇完整疗程的存在与较高的智力发育指数得分相关。

结论

产前接触苯巴比妥对18至22个月大早产儿的神经发育结局没有有利或不利影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验